학술논문
INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA–RELATED CYSTOID MACULAR EDEMA
Document Type
Academic Journal
Author
Mansour, Ahmad M.; Sheheitli, Huda; Kucukerdonmez, Cem; Sisk, Robert A.; Moura, Raphael; Moschos, Marilita M.; Lima, Luiz H.; Al-Shaar, Laila; Arevalo, J. Fernando; Maia, Mauricio; Foster, Robert E.; Kayikcioglu, Ozcan; Kozak, Igor; Kurup, Shree; Zegarra, Hernando; Gallego-Pinazo, Roberto; Hamam, Rola N.; Bejjani, Riad A.; Cinar, Esat; Erakgün, Ethem T.; Kimura, Alan; Teixeira, Anderson
Source
Retina. Feb 01, 2018 38(2):416-423
Subject
Language
English
ISSN
0275-004X
Abstract
PURPOSE:: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. METHODS:: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. RESULTS:: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16–57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (μm) decreased from 506 ± 288 μm to 311.7 ± 71.6 μm (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1–7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. CONCLUSION:: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.